Phaseline

Targets › DECTIN1

DECTIN1 (C-type lectin domain family 7 member A): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Sep 2027.

Lectin that functions as a pattern recognizing receptor (PRR) specific for beta-1,3-linked and beta-1,6-linked glucans, which constitute cell wall constituents from pathogenic bacteria and fungi. Necessary for the TLR2-mediated inflammatory response and activation of NF-kappa-B: upon beta-glucan binding, recruits SYK via its ITAM motif and promotes a signaling cascade that activates some CARD domain-BCL10-MALT1…. (UniProt, Q9BXN2)

Open in Phaseline: the race on DECTIN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Abramson Cancer Center at Penn MedicineOdetiglucan
Dectin-1 agonist
DECTIN1Phase 2Colorectal Adenocarcinoma Metastatic in the LiverSep 2027
University of PennsylvaniaOdetiglucan
Dectin-1 agonist
DECTIN1Phase 2Pancreatic Ductal AdenocarcinomaOct 2027

Conditions

Pancreatic Ductal Adenocarcinoma (1) Colorectal Adenocarcinoma Metastatic in the Liver (1)

Modalities

mixed (2)

Companies

University of Pennsylvania (1) Abramson Cancer Center at Penn Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.